Lapatinib
Carcinoma, Ductal, Breast
West German Study GroupSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
10 Active assets in the Carcinoma, Ductal, Breast cohort.
View all 35 →
Same molecule, other indications
Lapatinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →